| Company | Product | Type/Indication | 1993 | 1994 | 1995 | 1996 | 1997* |
| Sales(M) | Sales(M) | Sales(M) | Sales(M) | Sales (M) | |||
| Amgen Inc. | Epogen | Erythropoietin/anemia in | $586 | $721 | $883 | $1,071 | $1,161 |
| kidney failure | |||||||
| Amgen Inc. | Neupogen | Granulocyte colony stimu- | $719 | $829 | $936 | $1,017 | $1,056 |
| lating factor/neutropenia | |||||||
| in chemotherapy | |||||||
| BioChem Pharma | 3TC | Epivir; nucleoside analogue/ | — | — | 11/95 | C$429 | C$973# |
| Inc. (and Glaxo | combination therapy with | (FDA- | |||||
| Wellcome plc) | AZT for treating AIDS | approved) | |||||
| Biogen Inc. | Avonex | Interferon-beta/ | — | — | — | $77 | $240 |
| multiple sclerosis | (5/96 FDA- | ||||||
| approved) | |||||||
| Centocor Inc. | ReoPro | Chimeric monoclonal | — | 12/94 | $23 | $149 | $254@ |
| (and Eli Lilly & Co.) | antibody to GPIIb/IIIa platelet | (FDA- | |||||
| receptor/reduction of acute | approved) | ||||||
| cardiac events in angina, | |||||||
| angioplasty patients | |||||||
| Genentech Inc. | Activase | Tissue plasminogen | $236 | $281 | $301 | $284 | $261 |
| activator/myocardial | |||||||
| infarct; pulmonary embolism | |||||||
| Genentech Inc. | Protropin/ | Human growth hormone/ | $217 | $225 | $219 | $218 | $224 |
| Neutropin/ | growth hormone inade- | ||||||
| Neutropin | quacy in children; chronic | ||||||
| AQ | renal insufficiency | ||||||
| Genentech Inc. | Pulmozyme | Human DNase/ | 12/93 | $88 | $111 | $76 | $92 |
| cystic fibrosis | (FDA- | ||||||
| approved) | |||||||
| Genzyme Corp. | Ceredase/ | Glucocerebrosidase/ | $125 | $172 | $215 | $265 | $333 |
| Cerezyme | Gaucher's disease | ||||||
| Immunex Corp. | Leukine | Granulocyte macro- | $43 | $46 | $41 | $43 | $53 |
| phage colony stim- | |||||||
| ulating factor/bone | |||||||
| marrow engraftment | |||||||
| NOTES: | |||||||
| * All sales figures were derived from company earnings reports or from analysts' reports. In general, these figures represent total sales in all territories. In some instances, as noted separately, they represent revenues to the company rather than total sales. | |||||||
| # Sales figures for 3TC are quoted in Canadian dollars and represent worldwide sales by Glaxo Wellcome plc (of which BioChem Pharma Inc. gets about 14 percent in royalties on U.S. sales and slightly less elsewhere). BioChem Pharma got C$124.1M in royalties in fiscal 1997 and C$57.1M in royalties in fiscal 1996 . | |||||||
| @ Sales figures for ReoPro are end sales to customers as reported by Centocor Inc.'s marketing partner, Eli Lilly & Co. , with whom Centocor is to split proceeds 50/50. In fiscal 1997, Centocor sold $158.4M of ReoPro to Lilly; for fiscal 1996, Centocor sold $88.7M to Lilly and for fiscal 1995, Centocor sold $15.5M of ReoPro to Lilly. | |||||||
